Home / Reports


Physicians’ views on biosimilars labelling

On 23 March 2015, the Alliance for Safe Biologic Medicines (ASBM), which represents patients and physicians, as well as originator biological and biosimilars companies in the US, released results of a survey, which showed that physicians ‘support transparent, clear labels with data that enables prescribers to learn about and evaluate the medicines available to their patients’ [1].

US biosimilars approvals expected to increase despite challenges

Biosimilar approvals in the US are expected to increase during the next five years, despite safety and regulatory challenges, according to a study from the Boston-based Tufts Center for the Study of Drug Development (CSDD).

Biosimilars will only be developed for blockbuster biologicals

A new report, published on 24 February 2015, by pharmacy benefits management (PBM) company Prime Therapeutics, suggests that only blockbuster biologicals in the US will be subject to biosimilar competition in the future.

Brazil looks to follow-on biological products to contain costs

Brazil’s Government is looking at measures to control the rising cost of healthcare. With increasing demand for life-saving biologicals the government is considering follow-on biological products as a more cost-effective option [1].

Generics gaining ground in French pharmaceutical market

The French pharmaceutical market is forecast to grow by a miniscule amount in the coming years due to the growing influence of generics in the country.

US pay-for-delay deals decrease in 2013

During 2013, companies filed a total of 145 final patent dispute settlements, of which 29 were potentially anticompetitive or ‘pay-for-delay’ agreements between brand-name and generics companies, according to a new report released on 22 December 2014 by the US Federal Trade Commission (FTC).

Generics still cost more in Canada, but prices decreasing

A report issued in December 2014 by Canada’s Patented Medicine Prices Review Board (PMPRB) finds that the prices of generics in Canada have decreased significantly in recent years. However, Canadians are still paying more for their generics than patients in many other countries.

EU problematic patent settlements stabilize

The number of patent settlements between originator and generics companies concluded during 2013 has reduced compared to 2012. While the number of problematic or so-called ‘pay-for-delay’ deals have stabilized compared to 2012.

Biosimilars could save US$44.2 billion over 10 years

Introducing biosimilars of complex biologicals used to treat illnesses such as cancer and rheumatoid arthritis could cut spending on biologicals in the US by US$44 billion over the next decade, according to an analysis carried out by the RAND Corporation.

UK uses less brand-name medicines per person

The UK uses fewer brand-name medicines per person than many other countries, but this means that the country tends to use older medicines rather than the latest ones, according to a new report.

Generics News Research General


Biosimilars News Research General